Dimerix

Dimerix Accounts Payable

The Accounts Payable of Dimerix (DXB.AX) as of Oct 11, 2026 is 2.28 M AUD. In the previous year, Accounts Payable was 14.08 M AUD — a change of -83.79% (lower).

Accounts Payable

2.28 MAUD

YoY

-83.79%

Last updated:

Accounts Payable of Dimerix is 2026 2.28 M AUD. Accounts Payable of Dimerix was 2025 14.08 M AUD. It decreases by -83.79% lower compared to the previous year.

The Dimerix Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
416,821.00 AUD
Jan 1, 2020
1.15 M AUD
Jan 1, 2021
2.52 M AUD
Jan 1, 2022
1.11 M AUD
Jan 1, 2023
5.14 M AUD
Jan 1, 2024
305,162.00 AUD
Jan 1, 2025
14.08 M AUD
Jan 1, 2026
2.28 M AUD
The Dimerix Accounts Payable history
YEARAccounts PayableYoY
2.28 MAUD-83.79%
14.08 MAUD+4,514.92%
305,162.00AUD-94.06%
5.14 MAUD+362.46%
1.11 MAUD-55.93%
2.52 MAUD+119.37%
1.15 MAUD+175.64%
416,821.00AUD+54.80%
269,262.00AUD+222.86%
83,399.00AUD-37.42%
133,273.00AUD-1.94%
135,909.00AUD+32.12%
102,866.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Accounts Payable of Dimerix is 2.28 M AUD in 2026.

Accounts Payable of Dimerix changed from 14.08 M AUD to 2.28 M AUD, representing a -83.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Dimerix since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Dimerix historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Dimerix

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Dimerix